Evidence map›Paper›PMID 30110936›Full record

ReviewInternational journal of molecular sciences2018

Biological Aspects of mTOR in Leukemia.

Simone Mirabilii, Maria Rosaria Ricciardi, Monica Piedimonte, Valentina Gianfelici, Maria Paola Bianchi, Agostino Tafuri

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. mTOR in Human Diseases.International journal of molecular sciences · 2019
    Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Simone MirabiliiLaboratory of Cell Kinetics and Applied Proteomics, Faculty of Medicine and Psychology, Department of Clinic and Molecular Medicine, Sapienza University of Rome, via Rovigo 1, 00161 Rome, Italy. simone.mirabilii@uniroma1.it.
Maria Rosaria RicciardiLaboratory of Cell Kinetics and Applied Proteomics, Faculty of Medicine and Psychology, Department of Clinic and Molecular Medicine, Sapienza University of Rome, via Rovigo 1, 00161 Rome, Italy. mariarosaria.ricciardi@uniroma1.it.
Monica PiedimonteLaboratory of Cell Kinetics and Applied Proteomics, Faculty of Medicine and Psychology, Department of Clinic and Molecular Medicine, Sapienza University of Rome, via Rovigo 1, 00161 Rome, Italy. monica.piedimonte@uniroma1.it.
Valentina GianfeliciLaboratory of Cell Kinetics and Applied Proteomics, Faculty of Medicine and Psychology, Department of Clinic and Molecular Medicine, Sapienza University of Rome, via Rovigo 1, 00161 Rome, Italy. gianfelici@bce.uniroma1.it.
Maria Paola BianchiLaboratory of Cell Kinetics and Applied Proteomics, Faculty of Medicine and Psychology, Department of Clinic and Molecular Medicine, Sapienza University of Rome, via Rovigo 1, 00161 Rome, Italy. mariapaolabianchi82@gmail.com.
Agostino TafuriLaboratory of Cell Kinetics and Applied Proteomics, Faculty of Medicine and Psychology, Department of Clinic and Molecular Medicine, Sapienza University of Rome, via Rovigo 1, 00161 Rome, Italy. agostino.tafuri@uniroma1.it.
Sapienza University of Rome · ITAzienda Ospedaliera Sant'Andrea · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mammalian target of rapamycin (mTOR) is a central processor of intra- and extracellular signals, regulating many fundamental cellular processes such as metabolism, growth, proliferation, and survival. Strong evidences have indicated that mTOR dysregulation is deeply implicated in leukemogenesis. This has led to growing interest in the development of modulators of its activity for leukemia treatment. This review intends to provide an outline of the principal biological and molecular functions of mTOR. We summarize the current understanding of how mTOR interacts with microRNAs, with components of cell metabolism, and with controllers of apoptotic machinery. Lastly, from a clinical/translational perspective, we recapitulate the therapeutic results in leukemia, obtained by using mTOR inhibitors as single agents and in combination with other compounds.

Indexed as

AnimalsApoptosisCell Transformation, NeoplasticHumansLeukemiaMicroRNAsNeoplasm ProteinsProtein Kinase InhibitorsRNA, NeoplasmTOR Serine-Threonine KinasesMicroRNAsMTOR protein, humanNeoplasm ProteinsProtein Kinase InhibitorsRNA, NeoplasmTOR Serine-Threonine Kinasesapoptosiscell signalingleukemiametabolismmiRNAmTOR inhibitors

Identifiers

PMID30110936
PMCPMC6121663
OpenAlexW2885655350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.